By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Wednesday that its board of directors has authorized the purchase of up to 1 million shares of the firm's common stock, but not more than $21 million in aggregate purchase price.

Luminex said that the repurchase program will run through November 2011. The purchases will be made from time to time on the open market or through privately negotiated transactions. Luminex currently has 42.3 million shares outstanding.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.